Chase Pharmaceuticals Corporation raises $21 million in a Series B financing round led by New Rhein Healthcare Investors, LLC.
Edmond de Rothschild Investment Partners
Breaking News
- Taylor Swift Reaches Her Billionaire' Era,' Joining Elon Musk and Jeff Bezos on the List of World's Wealthiest People
- Biden Administration to Provide $1.5 Billion Loan to Reopen Michigan Nuclear Power Plant, a First in the US
- Four Deaths May Be Linked to Dietary Supplements Made by Japan’s Kobayashi Pharmaceutical: Report
Axonics Modulation Technologies Inc has bagged $32.6 million for its Series A preferred stock financing round led by Edmond de Rothschild Investment Partners, a statement about the funding said.
Edmond de Rothschild raises EUR192 million or USD250 million for its BioDiscovery 4 fund.
Complix completed its Series B funding as Edmond de Rothschild Investment Partners and GMIV handed their support.
Subscribe to VCpost newsletter
Most Popular
- Former CEO Shoots Himself to Commit Suicide After Receiving $25 Million Record-Breaking Fine for Fraud at Steinhoff
- Xi Jinping Warns Dutch PM That 'No Force' Can Stop China's Technological Advancement Amid Export Restrictions
- Major AI Companies Unite to Create the World's First Artificial Superintelligence Alliance Worth $7.6 Billion
- Social Security Benefits to Increase for Some Seniors After Addressing Overpayment Issues
- Disney Investor Nelson Peltz Criticizes the Company’s 'Woke' Strategy, Questioning 'Black Panther' and 'The Marvels' Films
- Citigroup to Complete Sweeping Overhaul This Week After Laying Off 5,000 Employees
- Disney, Florida Gov. Ron DeSantis' Allies Settle Lawsuit Over Disney World Special District, Ending Feud Over 'Don't Say Gay' Law
- North Korea Refuses Peace Talk With Japan Unless They Confront Their 'Brutal' History; Business Relations at Risk